Quick Comparison

Citicoline (CDP-Choline)NAC
Half-Life56-71 hours (sustained release characteristics)5.6 hours
Typical DosageStandard: 250-500 mg daily. Clinical studies use 500-2000 mg daily. Take in the morning — mildly stimulating. Cognizin is the most studied form. Can be split into 2 doses. Often combined with racetams to provide the choline needed for enhanced acetylcholine turnover.Standard: 600-1800 mg daily in 1-2 divided doses. Clinical (OCD/addiction): 1200-2400 mg daily. Take on an empty stomach for best absorption. Some practitioners combine with Vitamin C to enhance glutathione recycling.
AdministrationOral (capsules, powder). Cognizin branded form is most studied. Take in the morning.Oral (capsules, powder). Take on an empty stomach. Unpleasant sulfur taste in powder form.
Research Papers10 papers10 papers
Categories

Mechanism of Action

Citicoline (CDP-Choline)

Citicoline (CDP-choline) is hydrolyzed in the gut by alkaline phosphatase to choline and cytidine-5'-monophosphate, which are absorbed separately and reassembled in the brain via the Kennedy pathway. Choline feeds two critical pathways: (1) Acetylcholine synthesis via choline acetyltransferase (ChAT) — the primary memory and learning neurotransmitter acting at muscarinic and nicotinic receptors. (2) Phosphatidylcholine synthesis via CTP:phosphocholine cytidylyltransferase — the structural component of neuronal membranes and synaptic vesicles. Cytidine is dephosphorylated to uridine, converted to UTP, and supports RNA synthesis and CDP-choline formation for synapse formation. Citicoline also activates SIRT1 (possibly via NAD+ modulation) and increases brain norepinephrine and dopamine (mechanism unclear — may enhance synthesis or release). It is the only choline source providing both cholinergic and membrane-building support in one molecule.

NAC

NAC is deacetylated to cysteine, the rate-limiting substrate for glutathione synthesis via gamma-glutamylcysteine synthetase and glutathione synthetase. Glutathione (GSH) is the primary intracellular antioxidant in neurons, neutralizing reactive oxygen species and maintaining redox balance. NAC also activates the cystine-glutamate antiporter (System Xc-, composed of SLC7A11 and SLC3A2 subunits), which exchanges extracellular cystine for intracellular glutamate in a 1:1 ratio. This non-vesicular mechanism modulates extrasynaptic glutamate levels, reducing NMDA receptor overactivation and excitotoxicity. The glutamate-modulating effect explains NAC's promise in OCD (reducing corticostriatal glutamate hyperactivity), addiction (normalizing nucleus accumbens glutamate after drug exposure), and neurodegenerative conditions involving glutamate dysregulation.

Risks & Safety

Citicoline (CDP-Choline)

Common

Headache (especially with racetams — indicates too much cholinergic stimulation), nausea, diarrhea.

Serious

None documented at standard doses.

Rare

Insomnia, blurred vision.

NAC

Common

Nausea, vomiting, diarrhea, foul-smelling breath.

Serious

May interact with blood thinners and nitroglycerin. Concern that antioxidants may reduce efficacy of chemotherapy (theoretical).

Rare

Bronchospasm (in people with asthma), anaphylactic-like reactions.

Full Profiles